在单倍体同种异体造血细胞移植中,聚乙二醇化粒细胞集落刺激因子动员的造血干细胞的移植效果可能优于 G-CSF 动员的造血干细胞的移植效果

IF 3.2 4区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Current Research in Translational Medicine Pub Date : 2024-09-20 DOI:10.1016/j.retram.2024.103473
Junjie Cao , Xianxu Zhuang , Renzhi Pei , Ying Lu , Peipei Ye , Dong Chen , Xiaohong Du , Shuangyue Li , Xuhui Liu
{"title":"在单倍体同种异体造血细胞移植中,聚乙二醇化粒细胞集落刺激因子动员的造血干细胞的移植效果可能优于 G-CSF 动员的造血干细胞的移植效果","authors":"Junjie Cao ,&nbsp;Xianxu Zhuang ,&nbsp;Renzhi Pei ,&nbsp;Ying Lu ,&nbsp;Peipei Ye ,&nbsp;Dong Chen ,&nbsp;Xiaohong Du ,&nbsp;Shuangyue Li ,&nbsp;Xuhui Liu","doi":"10.1016/j.retram.2024.103473","DOIUrl":null,"url":null,"abstract":"<div><div>Granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells have become the preferred source of hematopoietic stem cells. We compared the effectiveness of G-CSF and pegylated G-CSF (peg-G-CSF) for hematopoietic stem cell mobilization in haploidentical hematopoietic stem cell transplantation (haplo-HSCT) donors, and evaluated the transplant outcomes. We conducted a matched retrospective cohort study. Donors mobilized with peg-G-CSF (<em>n</em> = 70) and G-CSF (<em>n</em> = 70). 140 consecutive patients diagnosed with acute leukemia who underwent haplo-HSCT were included in this study. The findings revealed that the peg-G-CSF cohort exhibited significantly elevated myeloid-derived suppressor cells (MDSCs) levels in their grafts when compared to the G-CSF cohort (<em>P</em> &lt; 0.001). The 100-day cumulative incidence (CI) of grade III-IV acute graft-versus-host disease (GVHD) and 1-year CI of moderate-to-severe chronic GVHD were 4.3% vs 14.3 % (<em>P</em> = 0.047) and 11.2% vs 27.4 % (<em>P</em> = 0.023), in the peg-G-CSF group and G-CSF group. Patients reveiving mobilized stem cell with peg-G-CSF had a significantly greater likelihood of 1-year GVHD-free relapse-free survival (GRFS) compared to patients reveiving mobilized stem cell with G-CSF (74.9% vs 37.9 %, <em>P</em> &lt; 0.001). The higher graft MDSCs proportion was associated with lower grade II-IV aGVHD, cGVHD (<em>P</em> &lt; 0.05) and higher GRFS in the univariate analysis (<em>P</em> &lt; 0.05). Multivariate analysis showed that MDSCs proportion higher than 11.36 % (HR, 0.305; 95 % CI, 0.154–0.606; <em>P</em> = 0.001) and peg-G-CSF for stem cell mobilization (HR, 0.466; 95 % CI, 0.251–0.865; <em>P</em> = 0.016) were independent prognostic factors of GRFS. The superior survival rates observed in recipients of peg-G-CSF-mobilized cells are likely due to reduced acute GVHD, potentially mediated by the increased MDSCs within the grafts.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 4","pages":"Article 103473"},"PeriodicalIF":3.2000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The transplantation effect of pegylated granulocyte colony-stimulating factor mobilized hematopoietic stem cells may be superior to that of G-CSF mobilized hematopoietic stem cells in haploidentical allogeneic hematopoietic cell transplantation\",\"authors\":\"Junjie Cao ,&nbsp;Xianxu Zhuang ,&nbsp;Renzhi Pei ,&nbsp;Ying Lu ,&nbsp;Peipei Ye ,&nbsp;Dong Chen ,&nbsp;Xiaohong Du ,&nbsp;Shuangyue Li ,&nbsp;Xuhui Liu\",\"doi\":\"10.1016/j.retram.2024.103473\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells have become the preferred source of hematopoietic stem cells. We compared the effectiveness of G-CSF and pegylated G-CSF (peg-G-CSF) for hematopoietic stem cell mobilization in haploidentical hematopoietic stem cell transplantation (haplo-HSCT) donors, and evaluated the transplant outcomes. We conducted a matched retrospective cohort study. Donors mobilized with peg-G-CSF (<em>n</em> = 70) and G-CSF (<em>n</em> = 70). 140 consecutive patients diagnosed with acute leukemia who underwent haplo-HSCT were included in this study. The findings revealed that the peg-G-CSF cohort exhibited significantly elevated myeloid-derived suppressor cells (MDSCs) levels in their grafts when compared to the G-CSF cohort (<em>P</em> &lt; 0.001). The 100-day cumulative incidence (CI) of grade III-IV acute graft-versus-host disease (GVHD) and 1-year CI of moderate-to-severe chronic GVHD were 4.3% vs 14.3 % (<em>P</em> = 0.047) and 11.2% vs 27.4 % (<em>P</em> = 0.023), in the peg-G-CSF group and G-CSF group. Patients reveiving mobilized stem cell with peg-G-CSF had a significantly greater likelihood of 1-year GVHD-free relapse-free survival (GRFS) compared to patients reveiving mobilized stem cell with G-CSF (74.9% vs 37.9 %, <em>P</em> &lt; 0.001). The higher graft MDSCs proportion was associated with lower grade II-IV aGVHD, cGVHD (<em>P</em> &lt; 0.05) and higher GRFS in the univariate analysis (<em>P</em> &lt; 0.05). Multivariate analysis showed that MDSCs proportion higher than 11.36 % (HR, 0.305; 95 % CI, 0.154–0.606; <em>P</em> = 0.001) and peg-G-CSF for stem cell mobilization (HR, 0.466; 95 % CI, 0.251–0.865; <em>P</em> = 0.016) were independent prognostic factors of GRFS. The superior survival rates observed in recipients of peg-G-CSF-mobilized cells are likely due to reduced acute GVHD, potentially mediated by the increased MDSCs within the grafts.</div></div>\",\"PeriodicalId\":54260,\"journal\":{\"name\":\"Current Research in Translational Medicine\",\"volume\":\"72 4\",\"pages\":\"Article 103473\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Research in Translational Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2452318624000357\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452318624000357","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

粒细胞集落刺激因子(G-CSF)动员的外周血干细胞已成为造血干细胞的首选来源。我们比较了G-CSF和聚乙二醇化G-CSF(peg-G-CSF)在单倍体造血干细胞移植(haplo-HSCT)供者中动员造血干细胞的效果,并评估了移植结果。我们进行了一项匹配的回顾性队列研究。使用 peg-G-CSF (70 人)和 G-CSF (70 人)动员的捐献者。本研究纳入了 140 名连续接受单倍体造血干细胞移植的急性白血病患者。研究结果显示,与G-CSF组相比,peg-G-CSF组移植物中的髓源性抑制细胞(MDSCs)水平明显升高(P < 0.001)。在peg-G-CSF组和G-CSF组中,III-IV级急性移植物抗宿主疾病(GVHD)的100天累积发病率(CI)和中度至重度慢性GVHD的1年CI分别为4.3% vs 14.3 %(P = 0.047)和11.2% vs 27.4 %(P = 0.023)。与接受G-CSF动员干细胞的患者相比,接受peg-G-CSF动员干细胞的患者1年无GVHD无复发生存率(GRFS)明显更高(74.9% vs 37.9%,P <0.001)。在单变量分析中,移植物MDSCs比例越高,II-IV级aGVHD和cGVHD越低(P <0.05),GRFS越高(P <0.05)。多变量分析显示,MDSCs比例高于11.36%(HR,0.305;95 % CI,0.154-0.606;P = 0.001)和用于干细胞动员的peg-G-CSF(HR,0.466;95 % CI,0.251-0.865;P = 0.016)是GRFS的独立预后因素。接受peg-G-CSF动员细胞的受者生存率较高,这可能是由于移植物中MDSCs增加,从而减少了急性GVHD。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The transplantation effect of pegylated granulocyte colony-stimulating factor mobilized hematopoietic stem cells may be superior to that of G-CSF mobilized hematopoietic stem cells in haploidentical allogeneic hematopoietic cell transplantation
Granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells have become the preferred source of hematopoietic stem cells. We compared the effectiveness of G-CSF and pegylated G-CSF (peg-G-CSF) for hematopoietic stem cell mobilization in haploidentical hematopoietic stem cell transplantation (haplo-HSCT) donors, and evaluated the transplant outcomes. We conducted a matched retrospective cohort study. Donors mobilized with peg-G-CSF (n = 70) and G-CSF (n = 70). 140 consecutive patients diagnosed with acute leukemia who underwent haplo-HSCT were included in this study. The findings revealed that the peg-G-CSF cohort exhibited significantly elevated myeloid-derived suppressor cells (MDSCs) levels in their grafts when compared to the G-CSF cohort (P < 0.001). The 100-day cumulative incidence (CI) of grade III-IV acute graft-versus-host disease (GVHD) and 1-year CI of moderate-to-severe chronic GVHD were 4.3% vs 14.3 % (P = 0.047) and 11.2% vs 27.4 % (P = 0.023), in the peg-G-CSF group and G-CSF group. Patients reveiving mobilized stem cell with peg-G-CSF had a significantly greater likelihood of 1-year GVHD-free relapse-free survival (GRFS) compared to patients reveiving mobilized stem cell with G-CSF (74.9% vs 37.9 %, P < 0.001). The higher graft MDSCs proportion was associated with lower grade II-IV aGVHD, cGVHD (P < 0.05) and higher GRFS in the univariate analysis (P < 0.05). Multivariate analysis showed that MDSCs proportion higher than 11.36 % (HR, 0.305; 95 % CI, 0.154–0.606; P = 0.001) and peg-G-CSF for stem cell mobilization (HR, 0.466; 95 % CI, 0.251–0.865; P = 0.016) were independent prognostic factors of GRFS. The superior survival rates observed in recipients of peg-G-CSF-mobilized cells are likely due to reduced acute GVHD, potentially mediated by the increased MDSCs within the grafts.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Research in Translational Medicine
Current Research in Translational Medicine Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology
CiteScore
7.00
自引率
4.90%
发文量
51
审稿时长
45 days
期刊介绍: Current Research in Translational Medicine is a peer-reviewed journal, publishing worldwide clinical and basic research in the field of hematology, immunology, infectiology, hematopoietic cell transplantation, and cellular and gene therapy. The journal considers for publication English-language editorials, original articles, reviews, and short reports including case-reports. Contributions are intended to draw attention to experimental medicine and translational research. Current Research in Translational Medicine periodically publishes thematic issues and is indexed in all major international databases (2017 Impact Factor is 1.9). Core areas covered in Current Research in Translational Medicine are: Hematology, Immunology, Infectiology, Hematopoietic, Cell Transplantation, Cellular and Gene Therapy.
期刊最新文献
DNMT3A-related overgrowth syndrome presenting with immune thrombocytopenic purpura Evaluation and management of hepatic dysfunction, portal hypertension and portal/splanchnic vein thrombosis in patients with myelofibrosis undergoing allogeneic haematopoietic cell transplantation: A practice based survey on behalf of the Chronic Malignancies Working Party of the EBMT. CAR T-cell therapy combined with autologous hematopoietic cell transplantation in patients with refractory/relapsed Burkitt Lymphoma In silico analysis and structural vaccinology prediction of Toxoplasma gondii ROP41 gene via immunoinformatics methods as a vaccine candidate Effect and safety of recombinant human thrombopoietin on haematopoietic reconstitution after allogeneic haematopoietic cell transplantation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1